reductase

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase with an IC50 value of 28.9 pM, which can target the relaxin hormone signaling pathway in prostate cancer models.

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors.

Trimethoprim (NSC-106568) is a Dihydrofolate Reductase Inhibitor Antibacterial. The mechanism of action of trimethoprim is as a Dihydrofolate Reductase Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Organic Cation Transporter 2 Inhibitor.

Glutathione reductase (EC 1.6.4.2) is an enzyme that maintains the supply of reduced glutathione [1].

5α-reductase-IN-1 is a potent inhibitor of the enzyme 5α-reductase. This compound is primarily employed in research studies to investigate its potential efficacy in treating patterned alopecia. It is commonly used in combination with minoxidil, a well-known treatment for hair loss.

Thioredoxin reductase peptide acetate corresponds to residues 53–67 in thioredoxin reductase (TrxR), used in thioredoxin reductase research.Mammalian thioredoxin reductase (TR) catalyzes the reduction of the redox-active disulfide bond of thioredoxin (Trx

Aldose reductase-IN-4 (compound IIc) is an inhibitor of aldose reductase with IC50 values of 11.70 μM for ALR1 and 0.98 μM for ALR2, respectively [1].

Aldose reductase-IN-5 is an inhibitor of aldose reductase (ALR2) that enhances the combination of inhibitory excitability and antioxidant capacity, thereby delaying the diabetes complications progress.

Aldose reductase-IN-3 (Compound 5) is an effective and moderately selective aldose reductase (AR) inhibitor (IC50=3.99 μM) with research potential in sepsis, a molecular target involved in various inflammatory diseases (including sepsis).

Aldose reductase-IN-6 (Compound 3) is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki of 0.018 μM. Notably, Aldose reductase-IN-6 demonstrates no cytotoxicity toward normal cells [1].

Aldose reductase-IN-2 (Compound 5f) is a potent aldose reductase (AR) inhibitor with antioxidant properties, making it a promising drug for anti-diabetic complications.

Thioredoxin reductase peptide TFA, corresponding to residues 53-67 in thioredoxin reductase (TrxR), is utilized in thioredoxin reductase research.

Thioredoxin reductase peptide, corresponding to residues 53-67 in thioredoxin reductase (TrxR), is used in thioredoxin reductase research. Mammalian thioredoxin reductase (TR) catalyzes the reduction of the redox-active disulfide bond of thioredoxin (Trx) and is structurally and mechanistically similar to glutathione reductase, except for a C-terminal 16-amino acid extension containing a rare vicinal selenylsulfide bond.

HMG-CoA Reductase-IN-1, an inhibitor of HMG-CoA reductase, demonstrates strong inhibitory activity on HMGR and affinity for OATP1B1, with pIC50 and pKm values of 8.54 and 1.98, respectively. It is utilized in hypercholesterolemia research [1].

Cytochrome P450 reductase, a NADPH-cytochrome reductase, facilitates an optimal conformation of aromatase for substrate binding [1].

Xanthine oxidoreductase-IN-5 is an orally active inhibitor of xanthine oxidoreductase (XOR) with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 may be used in studies of acute hyperuricemia.

Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 of 26.3 nM, suitable for use in acute hyperuricemia studies.

Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 29.3 nM, useful for studying hyperuricemia.

Xanthine oxidoreductase-IN-2 (Compound IVa) is a potent xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 7.2 nM, demonstrating hypouricemic effects in mice as evidenced by [1].

Xanthine oxidoreductase-IN-1 is a xanthine oxidoreductase (XOR) inhibitor with an IC 50 value of 7.0 nM.

Alconil (Al 1567) is an aldose reductase inhibitor that may be used to study chronic obstructive pulmonary disease (COPD) and diabetes.

Epristeride (ONO-9302) is an orally active, selective and non-competitive steroidal 5-α-reductase isoform 2 inhibitor that inhibits SR isoform 2.Episteride reduces prostate size and improves symptoms in men with BPH.Episteride induces atrophy and apoptosis of the ventral prostate in rats.

MK 0434 is an orally active steroidal 5 alpha-reductase inhibitor.

Alpha-Estradiol (Epiestradiol) is an estrogen that inhibits 5alpha-reductase and has potential in the study of androgenetic alopecia.